Aktienanalyse zu Sonoma Pharmaceuticals Inc (SNOA)SNOASonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sonoma Pharmaceuticals Inc (SNOA) appears to be a good buy right now due to its recent FDA clearance for the Microdacyn Wound Solution, which is expected to enhance market competitiveness. The stock is currently priced at $1.11, significantly below its 52-week high of $3.95, indicating potential for upside. Additionally, the company reported a 48.3% year-over-year revenue increase in Q4 2026, reaching $5.56 million, which reflects a strong recovery trend. However, a key risk is the forward P/E ratio of 46.08, suggesting that the stock may be overvalued relative to its earnings potential.

2 analysts cover SNOA: 2 rate it Buy, 0 Hold and 0 Sell.